Insmed reported $10.84M in Cost of Sales for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cost Of Sales Change
Acelrx Pharmaceuticals ACRX:US $ 1.04M 0M
Alexion Pharmaceuticals ALXN:US $ 125.4M 26.8M
Alimera Sciences ALIM:US $ 1.81M 0.25M
Biomarin Pharmaceutical BMRN:US $ 127.06M 6.9M
Dynavax Technologies DVAX:US $ 14.84M 9.78M
Flexion Therapeutics FLXN:US $ 4.98M 1.11M
Gilead Sciences GILD:US $ 1390M 29M
Heron Therapeutics HRTX:US $ 14.52M 5.32M
Insmed INSM:US $ 10.84M 993K
Novartis NVS:US $ 3754M 79M
Regeneron Pharmaceuticals REGN:US $ 693.7M 385.7M
Sarepta Therapeutics SRPT:US $ 19.52M 2.83M
Seattle Genetics SGEN:US $ 78.09M 13.96M
Ultragenyx Pharmaceutical RARE:US $ 3.14M 2.05M
Vertex Pharmaceuticals VRTX:US $ 227.97M 35.64M